Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Novel insights into the treatment of complement-mediated hemolytic anemias.

Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M.

Ther Adv Hematol. 2019 Sep 9;10:2040620719873321. doi: 10.1177/2040620719873321. eCollection 2019. Review.

2.

Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.

Hill QA, Hill A, Berentsen S.

Blood Adv. 2019 Jun 25;3(12):1897-1906. doi: 10.1182/bloodadvances.2019000036. Review.

3.

Cold agglutinin disease: current challenges and future prospects.

Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE.

J Blood Med. 2019 Apr 9;10:93-103. doi: 10.2147/JBM.S177621. eCollection 2019.

4.

Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence?

Sefland Ø, Randen U, Berentsen S.

Case Rep Hematol. 2019 Mar 4;2019:1610632. doi: 10.1155/2019/1610632. eCollection 2019.

5.

A three year-old boy with back pain, fever and cola-coloured urine.

Kvistad SAS, Gunnes MW, Hagen KG, Berentsen S.

Tidsskr Nor Laegeforen. 2019 Mar 18;139(6). doi: 10.4045/tidsskr.18.0532. Print 2019 Mar 26. English, Norwegian. No abstract available.

6.

Cold agglutinins: fending off the attack.

Berentsen S.

Blood. 2019 Feb 28;133(9):885-886. doi: 10.1182/blood-2019-01-894303. No abstract available.

PMID:
30819775
7.

Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease.

Berentsen S.

Semin Hematol. 2018 Jul;55(3):141-149. doi: 10.1053/j.seminhematol.2018.04.002. Epub 2018 Apr 10. Review.

PMID:
30032751
8.

How I manage patients with cold agglutinin disease.

Berentsen S.

Br J Haematol. 2018 May;181(3):320-330. doi: 10.1111/bjh.15109. Epub 2018 Jan 24. Review.

PMID:
29363757
9.

[A man in his 50s with fever and anemia].

Nordtveit S, Lerum TV, Ghanima W, Berentsen S.

Tidsskr Nor Laegeforen. 2018 Jan 22;138(2). doi: 10.4045/tidsskr.17.0460. Print 2018 Jan 23. Norwegian. No abstract available.

10.

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.

Fluge Ø, Mannsåker B, Torp A, Mjaaland I, Helgeland L, Klos J, Mella O, Berentsen S, Meyer P.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):125-135.e3. doi: 10.1016/j.clml.2017.12.002. Epub 2017 Dec 24.

11.

Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease.

Małecka A, Trøen G, Tierens A, Østlie I, Małecki J, Randen U, Wang J, Berentsen S, Tjønnfjord GE, Delabie JMA.

Br J Haematol. 2018 Dec;183(5):838-842. doi: 10.1111/bjh.15063. Epub 2017 Dec 19. No abstract available.

PMID:
29265349
12.

Neutrophil aggregation on the peripheral blood smear in a patient with cold agglutinin disease.

Berentsen S.

Ann Hematol. 2017 Oct;96(10):1767-1768. doi: 10.1007/s00277-017-3077-8. Epub 2017 Jul 27. No abstract available.

PMID:
28752395
13.

Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.

Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE.

Blood. 2017 Jul 27;130(4):537-541. doi: 10.1182/blood-2017-04-778175. Epub 2017 May 22.

PMID:
28533306
14.

Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease.

Tjønnfjord E, Vengen ØA, Berentsen S, Tjønnfjord GE.

BMJ Case Rep. 2017 May 9;2017. pii: bcr-2016-219066. doi: 10.1136/bcr-2016-219066.

15.

Cold agglutinin disease.

Berentsen S.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):226-231. Review.

16.

Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity.

Małecka A, Trøen G, Tierens A, Østlie I, Małecki J, Randen U, Berentsen S, Tjønnfjord GE, Delabie JM.

Haematologica. 2016 Sep;101(9):e361-4. doi: 10.3324/haematol.2016.146126. Epub 2016 May 19. No abstract available.

17.

Role of Complement in Autoimmune Hemolytic Anemia.

Berentsen S.

Transfus Med Hemother. 2015 Sep;42(5):303-10. doi: 10.1159/000438964. Epub 2015 Sep 7. Review.

18.

Cold agglutinin-mediated autoimmune hemolytic anemia.

Berentsen S, Randen U, Tjønnfjord GE.

Hematol Oncol Clin North Am. 2015 Jun;29(3):455-71. doi: 10.1016/j.hoc.2015.01.002. Epub 2015 Mar 12. Review.

PMID:
26043385
19.

Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.

Berentsen S, Sundic T.

Biomed Res Int. 2015;2015:363278. doi: 10.1155/2015/363278. Epub 2015 Jan 29. Review.

20.

Complement, cold agglutinins, and therapy.

Berentsen S.

Blood. 2014 Jun 26;123(26):4010-2. doi: 10.1182/blood-2014-04-568733.

PMID:
24970929
21.

Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.

Sundic T, Hervig T, Hannisdal S, Assmus J, Ulvik RJ, Olaussen RW, Berentsen S.

Blood Transfus. 2014 Jan;12 Suppl 1:s84-9. doi: 10.2450/2013.0128-13. Epub 2013 Oct 23.

22.

Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma.

Randen U, Trøen G, Tierens A, Steen C, Warsame A, Beiske K, Tjønnfjord GE, Berentsen S, Delabie J.

Haematologica. 2014 Mar;99(3):497-504. doi: 10.3324/haematol.2013.091702. Epub 2013 Oct 18.

23.

Therapy for chronic cold agglutinin disease: perspective for further improvements.

Berentsen S.

Blood Transfus. 2013 Apr;11(2):167-8. doi: 10.2450/2013.0273-12. Epub 2013 Jan 22. No abstract available.

24.

Iron chelation therapy in myelodysplastic syndrome.

Berentsen S.

Tidsskr Nor Laegeforen. 2012 Sep 18;132(17):1972-3. English, Norwegian. No abstract available.

25.

[Several diseases with the same clinical presentation].

Berentsen S.

Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):968. doi: 10.4045/tidsskr.12.0234. Norwegian. No abstract available.

26.

Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.

Berentsen S, Tjønnfjord GE.

Blood Rev. 2012 May;26(3):107-15. doi: 10.1016/j.blre.2012.01.002. Epub 2012 Feb 12. Review.

PMID:
22330255
27.

How I manage cold agglutinin disease.

Berentsen S.

Br J Haematol. 2011 May;153(3):309-17. doi: 10.1111/j.1365-2141.2011.08643.x. Epub 2011 Mar 8. Review.

PMID:
21385173
28.

High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.

Berentsen S, Randen U, Vågan AM, Hjorth-Hansen H, Vik A, Dalgaard J, Jacobsen EM, Thoresen AS, Beiske K, Tjønnfjord GE.

Blood. 2010 Oct 28;116(17):3180-4. doi: 10.1182/blood-2010-06-288647. Epub 2010 Jul 15.

PMID:
20634373
29.

[Autoimmune hemolytic anemia].

Berentsen S, Sundic T, Hervig T, Tjønnfjord GE.

Tidsskr Nor Laegeforen. 2009 Nov 5;129(21):2226-31. doi: 10.4045/tidsskr.09.0161. Review. Norwegian.

30.

Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia.

Berentsen S.

Clin Lymphoma Myeloma. 2009 Mar;9(1):110-2. doi: 10.3816/CLM.2009.n.030. Review.

PMID:
19362990
31.

[Neuropsychiatric disease with hematological findings].

Berentsen S.

Tidsskr Nor Laegeforen. 2009 Jan 1;129(1):35. Norwegian. No abstract available.

PMID:
19174852
32.

Rituximab for the treatment of autoimmune cytopenias.

Berentsen S.

Haematologica. 2007 Dec;92(12):1589-96. No abstract available.

33.

B-lymphocytes as targets for therapy in chronic cold agglutinin disease.

Berentsen S, Ulvestad E, Tjønnfjord GE.

Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):219-27. Review.

PMID:
17896962
34.

Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Berentsen S, Beiske K, Tjønnfjord GE.

Hematology. 2007 Oct;12(5):361-70. Review.

35.

[A three-year-old boy with bullous skin eruptions and paresis].

Borresen P, Taraldsrud E, Berentsen SA.

Tidsskr Nor Laegeforen. 2007 Aug 9;127(15):1950-2. Norwegian. No abstract available.

PMID:
17708060
36.

Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE.

Haematologica. 2006 Apr;91(4):460-6.

37.

[Lead poisoning].

Berentsen S.

Tidsskr Nor Laegeforen. 2005 Dec 15;125(24):3407. Norwegian. No abstract available.

38.

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjønnfjord GE.

Blood. 2004 Apr 15;103(8):2925-8. Epub 2003 Dec 30.

PMID:
15070665
39.

[Treatment of massive pulmonary embolism with local thrombolysis].

Egge J, Berentsen S, Storesund B, Rød R, Waage K.

Tidsskr Nor Laegeforen. 2002 Sep 30;122(23):2263-6. Norwegian.

40.

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.

Berentsen S, Tjønnfjord GE, Brudevold R, Gjertsen BT, Langholm R, Løkkevik E, Sørbø JH, Ulvestad E.

Br J Haematol. 2001 Oct;115(1):79-83.

PMID:
11722415
41.

Acute phase haemolysis in chronic cold agglutinin disease.

Ulvestad E, Berentsen S, Mollnes TE.

Scand J Immunol. 2001 Jul-Aug;54(1-2):239-42.

42.

No response to cladribine in five patients with chronic cold agglutinin disease.

Berentsen S, Tjønnfjord GE, Shammas FV, Bergheim J, Hammerstrøm J, Langholm R, Ulvestad E.

Eur J Haematol. 2000 Jul;65(1):88-90. No abstract available.

PMID:
10914950
43.

[Clinical significance of antibodies against red blood cells].

Berentsen S.

Tidsskr Nor Laegeforen. 1999 Nov 20;119(28):4239-40. Norwegian. No abstract available.

PMID:
10668390
44.

Clinical immunology of chronic cold agglutinin disease.

Ulvestad E, Berentsen S, Bø K, Shammas FV.

Eur J Haematol. 1999 Oct;63(4):259-66.

PMID:
10530415
45.

[Chronic myeloid leukemia in health regions 1, 3, 4 and 5 during the period 1990-96].

Lamvik J, Brinch L, Dahl IM, Sjo M, Nesthus I, Tangen JM, Berentsen S, Ly B, Shammas FV.

Tidsskr Nor Laegeforen. 1999 May 10;119(12):1733-6. Norwegian.

PMID:
10380587
46.

[Empirical antibiotic treatment of patients with acute myelogenous leukemia].

Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B.

Tidsskr Nor Laegeforen. 1999 Jan 10;119(1):35-8. Norwegian.

PMID:
10025202
47.

[Future requirements for hematologists].

Bruserud O, Berentsen S, Dahl IM, Grøttum K, Sletnes K.

Tidsskr Nor Laegeforen. 1998 Jun 20;118(16):2507-10. Norwegian.

PMID:
9667130
48.

[Large granular lymphocytic leukemia].

Berentsen S, Bruserud O, Ulvestad E.

Tidsskr Nor Laegeforen. 1998 Mar 10;118(7):1045-8. Norwegian.

PMID:
9531826
49.
50.

Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia.

Bruserud O, Ulvestad E, Halstensen A, Berentsen S, Bergheim J, Nesthus I.

Eur J Haematol. 1997 Nov;59(5):269-76.

PMID:
9414637

Supplemental Content

Loading ...
Support Center